INDEPENDENCE MALL WEST PHILADELPHIA, PA. 19105, U.S.A. TELEPHONE (215) 592-3000
CABLE ADDRESS: ROHMHAAS TELEX 845-247 TWX 710-670-5335 TELECOPIER (215) 592-3377

Contains NO CBI

ROHM AND HAAS COMPANY

A

August 26, 1992

8EHQ-92-12246
8892000 10465
INIT

Document Processing Center (TS-790)
Office of Toxic Substances
Attn: Section 8(e) Coordinator (CAP Agreement)
Environmental Protection Agency
401 M Street, S.W.
Washington, DC 20460

Dear Sir or Madam:

Re: 8(e) CAP-0103; Data Submission

The enclosed document is submitted pursuant to the TSCA Section 8(e) Compliance Audit Program and the CAP Agreement between Rohm and Haas Company and the Environmental Protection Agency. This document does not contain confidential business information.

The following is a summary of the contents of the submission under Unit II.C.3 of the CAP Agreement:

Tested Chemical:	1H-1,2,4-triazole-1-propanenitrile, alpha-[2-(4-chlorophenyl)-ethyl-alpha-phenyl-
CASRN:	114369-43-6
Title of Report or Study:	RH-7592: Oral (Gavage) Developmental Toxicity Screen in Rats (Report No. 87R-14)
Reportable Effect:	Judged to have embryotoxic effects on pregnant rats. Doses 50, 100, 150 mg/kg/day.

If additional information is required, please contact the undersigned at (215) 592-3139. Thank you.

Sincerely,

Ronald L. Keener

Ronald L. Keener, Ph.D.
Regulatory Affairs Director
Product Integrity Department

RLK:fs
Enclosure

9/27/95

cc: G. P. O'Hara
TD Central File

TD 87M-174

Spring House, February 18, 1987

To: P. K. Chan

From: H. M. Solomon

Subject: RH-7592: Data Summary

Attached is the data summary for RH-7592: Oral (Gavage) Developmental Toxicity Screen in Rats (Protocol No. 86P-485; Report No. 86R-014). The data summary has been reviewed by G. P. O'Hara and the raw data and a copy of the document sent to Archives. A copy of this data summary will be included as an appendix in the final report.

If you have any questions, please call.

H. M. Solomon

HMS/clk
Attachment

~~COMPANY CONFIDENTIAL~~
R. L. Keener SMS 6/18/91

RH-7592: Oral (Gavage) Developmental Toxicity Screen in Rats
Protocol No. 86P-485 Report No. 87R-014

Study conducted: October 7-28, 1986
Data Summary Finalized: February 17, 1987

Data Summary

RH-7592 technical, (Lot No. WS-9128, Toxicology Department Sample Number 86-201), containing 96.65% of the following active ingredient: 2-(2-(4-chlorophenyl-ethyl)-2-phenyl-1H-1,2,4-triazole-1-propanenitrile, was suspended in 0.5% aqueous methylcellulose and administered orally by gavage to four groups (12 rats/group) of presumed pregnant rats (Crl:CD®BR) at dosages of 0 (control), 50, 100 or 150 mg/kg on Days 6-15 of gestation (G). All doses were administered at a constant volume of 10 ml/kg. Clinical signs were taken at least once daily between Days 0-20 G. The dams were weighed on Days 0, 6, 8, 10, 13, 16, and 20 G. On Day 20 G the dams were killed and the thoracic and abdominal cavities were examined for gross changes. The gravid uterus was weighed and corpora lutea, implantation sites and resorptions were counted. The number of fetuses per litter were counted and their location within the uterus recorded. All fetuses were then weighed and examined for external alterations. Fetuses in the control and 150 mg/kg group also were examined for visceral and skeletal alterations.

No dams died in the control group or treated groups. No significant differences were noted between the control group and the 50 mg/kg group in the type or incidence of adverse clinical signs. At 100 and 150 mg/kg, a significant increase was noted in the incidence of scant feces during the treatment period (Days 6-15 G).

Mean maternal body weight and body weight gain was similar between the control group and 50 mg/kg group. Maternal body weight losses were noted among dams at 100 and 150 mg/kg on Day 8 G when compared to the control value. These losses were considered to be treatment-related. The adverse effect on maternal body weight was also demonstrated by a decrease in body weight gain among dams at 150 mg/kg between Days 8-10 g. The early loss in body weight among dams at 100 mg/kg was transient since body weight gain was similar to the control value by the end of the treatment period (Days 6-15 G.). At 150 mg/kg, the early loss in body weight (Days 6-8 G) and the decreased body weight gains (Days 8-10 G) resulted in significant decrease in body weight gain during the treatment period.

~~COMPANY CONFIDENTIAL~~
R. L. Keener/SMS 6-19-92

RH-7592: Oral (Gavage) Developmental Toxicity Screen in Rats
Protocol No. 86P-485 Report No. 87R-014

Data Summary

There were no treatment-related changes detected during the maternal postmortem examination.

There were no treatment-related changes evident in any of the reproductive parameters examined in the control group or 50 and 100 mg/kg groups. The number of litters produced, and the mean number per litter of corpora lutea, implantation, preimplantation loss, resorptions, dead and live fetuses and sex ratio were similar in these groups. A significant increase in total number of resorptions, particularly late resorptions, occurred at 150 mg/kg and was considered treatment-related.

Mean fetal body weight of male fetuses, female fetuses and both sexes combined was similar between the control group and the 50 and 100 mg/kg groups. A slight decrease in mean fetal body weight of male and female fetuses at 150 mg/kg was considered treatment-related even though the differences were not statistically significant.

There were no significant differences in the type or incidence of external malformations (0, 50, 100, and 150 mg/kg groups examined); or visceral and skeletal malformations (0 and 150 mg/kg groups examined) between the control and treated groups. A significant increase was noted in the total number of litters with malformed fetuses at 150 mg/kg when compared to the control value (control; 0 litters affected/11 litters examined vs. 150 mg/kg; 5 litters affected/10 litters examined). Each litter had one malformed fetus (omphalocele, 1 fetus; vestigial tail with anal atresia, 1 fetus; ventricular septal defect, 1 fetus; no innominate vessel, 1 fetus; and no 12th rib, 1 fetus). The increase appeared to be treatment-related however this result should be interpreted cautiously since the control value was unusually low (0.0% incidence of malformations), few litters were examined (11 control litters and 10 litters at 150 mg/kg), the 5 malformations seen at 150 mg/kg were considered unrelated and fetuses in the 50 and 100 mg/kg group were not examined for visceral and skeletal alterations.

The type and incidence of individual developmental variations and individual variations due to retarded development were similar between the control group and treated groups. There were no treatment-related differences between the control group and the treated groups in the total number of fetuses per litter with developmental variations or variations due to retarded development or in the total number of fetuses per litter with any type of variation.

CONFIDENTIAL

R.L. Keener/SKG 6-19-92

RH-7592: Oral (Gavage) Developmental Toxicity Screen in Rats
Protocol No. 86P-485 Report No. 87R-014

Data Summary

Conclusion

RH-7592, was administered orally by gavage to pregnant rats on Days 6-15 of gestation at dose levels up to and including 150 mg/kg of body weight. Maternal and embryofetal toxicity were demonstrated at 150 mg/kg. At 150 mg/kg, no significant increases were detected in the type or incidence of individual external, visceral or skeletal malformations. However, the total number of litters with malformed fetuses (five affected litters had one malformed fetus each) was significantly increased at the maternally toxic dose of 150 mg/kg. No definite conclusion can be made regarding these fetal malformations since their biological significance is questionable. This question should be resolved when the definitive study is completed.

R. L. Keener/SMG 6-18-92

RH-7592: Oral (Gavage) Developmental Toxicity Screen in Rats
Protocol No. 86P-485 Report No. 87R-014

BEST COPY AVAILABLE

Table 1: Female Mortality Rates

	DOSAGE	0 MG/KG/D	50 MG/KG/D	100 MG/KG/D	150 MG/KG/D
Females Mated	N	12	12	12	12
Died or Secd Moribund	N	0	0	0	0
	%	0.0	0.0	0.0	0.0
Non Pregnant	N				
	%				
Pregnant	N				
	%				
Females Pregnant	N	11	10	11	10
	%	92	83	92	83
Aborted	N	0	0	0	0
	%	0.0	0.0	0.0	0.0
Delivered Prematurely	N	0	0	0	0
	%	0.0	0.0	0.0	0.0
Examined at Scheduled Necropsy	N	12	12	12	12
	%	100	100	100	100
Non Pregnant	N	1	2	1	2
	%	8.3	17	8.3	17
Pregnant	N	11	10	11	10
	%	92	83	92	83
with all Resorptions	N	0	0	0	0
	%	0.0	0.0	0.0	0.0
with Viable Fetuses	N	11	10	11	10
	%	100	100	100	100

SIGNIFICANTLY DIFFERENT FROM CONTROL: a = P<0.05; b = P<0.01.

~~COMPANY CONFIDENTIAL~~

R. L. Keeney/SMG 6/19/92

RH-7592: Oral (Gavage) Developmental Toxicity Screen in Rats
Protocol No. 86P-485 Report No. 87R-014

BEST COPY AVAILABLE

Table 2: Incidence of Clinical Observations

DAY OF GESTATION	0 MG/KG/D	50 MG/KG/D	100 MG/KG/D	150 MG/KG/D
0 to 5				
NO SIGNIFICANT CLINICAL OBSERVATIONS	72/12	68/12	66/11	72/12
ALOPECIA, FOREPAW, BIL	0/ 0	3/ 1	3/ 1	0/ 0
ALOPECIA, FOREPAW, RT	0/ 0	0/ 0	4/ 1	0/ 0
6 to 15				
NO SIGNIFICANT CLINICAL OBSERVATIONS	187/11	186/10	107/11	84/12
VAGINA, DISCHARGE, RED	0/ 0	0/ 0	0/ 0	4/ 2
THIN	0/ 0	0/ 0	0/ 0	6/ 1
MOUTH, STAINED, RED	0/ 0	0/ 0	0/ 0	2/ 1
NOSE, STAINED, RED	0/ 0	0/ 0	0/ 0	2/ 1
ALOPECIA, FOREPAW, BIL	38/ 2	20/ 1	38/ 2	18/ 1
ALOPECIA, HIND LEG, RT.	19/ 1	20/ 1	15/ 1	0/ 0
ALOPECIA, HIP, BIL	20/ 1	0/ 0	0/ 0	34/ 2
ALOPECIA, FORELEG, BIL	0/ 0	20/ 1	0/ 0	0/ 0
ALOPECIA, CHEST	0/ 0	12/ 1	16/ 1	20/ 2
ALOPECIA, ABDOMEN	16/ 1	0/ 0	49/ 3	36/ 3
ALOPECIA, HIP, RT	0/ 0	0/ 0	16/ 1	20/ 2
SCAB, ABDOMEN	0/ 0	0/ 0	0/ 0	13/ 1
SCAB, LEG, HIND, RT	0/ 0	0/ 0	11/ 1	0/ 0
ALOPECIA, SIDE, RT	0/ 0	0/ 0	0/ 0	12/ 1
ALOPECIA, HIND LEG, BIL	0/ 0	0/ 0	10/ 1	0/ 0
SCAB, SIDE, RT	0/ 0	0/ 0	0/ 0	8/ 1
SCANT FECES	14/ 2	16/ 3	65/ 9*	110/11*
16 to 20				
NO SIGNIFICANT CLINICAL OBSERVATIONS	40/10	40/10	23/ 7	27/ 8
VAGINA, DISCHARGE, RED	0/ 0	0/ 0	0/ 0	3/ 2
CAGEBOARD, DISCHARGE, RED	0/ 0	0/ 0	2/ 2	1/ 1
ALOPECIA, FOREPAW, BIL	8/ 2	4/ 1	8/ 2	4/ 1
ALOPECIA, HIND LEG, RT.	4/ 1	4/ 1	4/ 1	0/ 0
ALOPECIA, HIP, BIL	4/ 1	0/ 0	0/ 0	8/ 2
ALOPECIA, FORELEG, BIL	0/ 0	4/ 1	0/ 0	0/ 0
ALOPECIA, CHEST	0/ 0	4/ 1	4/ 1	4/ 1
ALOPECIA, ABDOMEN	4/ 1	0/ 0	12/ 3	12/ 3
ALOPECIA, HIP, RT	0/ 0	0/ 0	4/ 1	8/ 2
ALOPECIA, SIDE, RT	0/ 0	0/ 0	0/ 0	4/ 1
ALOPECIA, HIND LEG, BIL	0/ 0	0/ 0	4/ 1	0/ 0
SCAB, SIDE, RT	0/ 0	0/ 0	0/ 0	4/ 1
SCANT FECES	0/ 0	0/ 0	4/ 3	3/ 3

~~COMPANY CONFIDENTIAL~~

R. C. Keener 6-19-92

RH-7592: Oral (Gavage) Developmental Toxicity Screen in Rats
Protocol No. 86P-485 Report No. 87R-014

BEST COPY AVAILABLE

Table 3: Mean Maternal Body Weight

	DOSAGE	0 MG/KG/D	50 MG/KG/D	100 MG/KG/D	150 MG/KG/D
No. of Females with Litters		11	10	11	10
DAY 0	MEAN	263	267	267	263
	S.E.	4.8	3.7	4.3	4.9
DAY 6	MEAN	287	291	290	288
	S.E.	5.3	3.8	4.6	5.4
DAY 8	MEAN	291	291	282	272
	S.E.	6.0	3.8	5.0	6.2
DAY 10	MEAN	298	302	295	276a
	S.E.	6.6	4.6	4.9	7.8
DAY 13	MEAN	310	315	310	295
	S.E.	6.7	4.5	5.2	6.7
DAY 16	MEAN	329	335	329	316
	S.E.	7.1	4.2	5.4	6.0
DAY 20	MEAN	389	399	393	377
	S.E.	9.1	5.7	6.8	7.7

SIGNIFICANTLY DIFFERENT FROM CONTROL: a = P<0.05; b = P<0.01.

~~COMPANY CONFIDENTIAL~~

R. C. Keenee ASMG 6/19/92

RH-7592: Oral (Gavage) Developmental
Toxicity Screen in Rats
Protocol No. 86P-485 Report No. 87R-014

BEST COPY AVAILABLE

Table 4: Mean Maternal Body Weight Changes

	DOSAGE	0 MG/KG/D	50 MG/KG/D	100 MG/KG/D	150 MG/KG/D
Females Treated	N	12	12	12	12
DAYS 0 TO 6	MEAN	23	24	24	25
	S.D.	5.1	5.5	9.0	6.9
	N	11	10	11	10
DAYS 6 TO 8	MEAN	4	0	-9b	-16b
	S.D.	5.0	3.9	6.5	7.7
	N	11	10	11	10
DAYS 8 TO 10	MEAN	8	10	13	4
	S.D.	6.7	6.4	4.2	11.9
	N	11	10	11	10
DAYS 10 TO 13	MEAN	12	13	15	19
	S.D.	5.8	3.3	2.6	11.4
	N	11	10	11	10
DAYS 13 TO 16	MEAN	19	20	19	21
	S.D.	5.0	3.4	4.2	7.7
	N	11	10	11	10
DAYS 6 TO 16	MEAN	42	43	38	28b
	S.D.	10.2	8.6	8.0	12.4
	N	11	10	11	10
DAYS 16 TO 20	MEAN	60	64	65	60
	S.D.	10.1	9.2	10.0	10.3
	N	11	10	11	10

SIGNIFICANTLY DIFFERENT FROM CONTROL: a = P<0.05; b = P<0.01.

~~COMPANY CONFIDENTIAL~~
R. L. Keener/SMG 6-19-92

RH-7592: Oral (Gavage) Developmental
Toxicity Screen in Rats
Protocol No. 86P-485 Report No. 87R-014

BEST COPY AVAILABLE

Table 5: Summary of Gross Postmortem Findings in Females

	DOSAGE	0 MG/KG/D	50 MG/KG/D	100 MG/KG/D	150 MG/KG/D
DAMS	N	12	12	12	12
UTERUS, FLUID FILLED, CLEAR	N	0	0	1	0

SIGNIFICANTLY DIFFERENT FROM CONTROL: a = P<0.05; b = P<0.01.

R. L. Keener/SWG 6-19-92

RH-7592: Oral (Gavage) Developmental Toxicity Screen in Rats
Protocol No. 86P-485 Report No. 87R-014

BEST COPY AVAILABLE

Table 6: Summary of Reproductive Outcome

	DOSAGE	0 MG/KG/D	50 MG/KG/D	100 MG/KG/D	150 MG/KG/D
Females Mated	N	12	12	12	12
Pregnant	N	11	10	11	10
	%	92	83	92	83
Aborted	N	0	0	0	0
Premature Births	N	0	0	0	0
Dams with Viable Fetuses	N	11	10	11	10
Dams with all Resorptions	N	0	0	0	0
Female Mortality	N	0	0	0	0
	%	0.0	0.0	0.0	0.0
Pregnant at C-section	N	11	10	11	10
	%	92	83	92	83
Corpora Lutea	MEAN	19.0	19.3	21.5	19.6
Implantation Sites	MEAN	14.9	16.2	16.8	15.3
Preimplantation Loss	MEAN%	18.1	13.7	25.0	20.2
Dead Fetuses	N	0	0	0	0
Resorptions Total	MEAN	1.1	1.4	1.8	3.0a
	MEAN%	7.6	8.1	11.4	20.7a
Early	MEAN	1.1	1.2	1.4	1.8
	MEAN%	7.6	6.9	8.5	12.3
Late	MEAN	0.0	0.2	0.5	1.2a
	MEAN%	0.0	1.3	2.9	8.4a
Live Fetuses	MEAN	13.8	14.8	14.2	12.3
	MEAN%	92.4	91.9	88.6	79.3a
Females	MEAN	7.1	7.3	7.8	6.0
Males	MEAN	6.7	7.5	6.4	6.3
	MEAN%	45.2	46.8	39.9	40.5
Live Fetal Body Weight (g)	MEAN	3.5	3.4	3.4	3.3
Male Fetuses	MEAN	3.6	3.5	3.4	3.3
Female Fetuses	MEAN	3.4	3.4	3.3	3.2

SIGNIFICANTLY DIFFERENT FROM CONTROL: a = P<0.05; b = P<0.01.

~~COMPANY CONFIDENTIAL~~

R. L. Keener/SMG 6-19-92

RH-7592: Oral (Gavage) Developmental Toxicity Screen in Rats
Protocol No. 86P-485 Report No. 87R-014

BEST COPY AVAILABLE

Table 7: Fetal Malformations

	DOSAGE	0 MG/KG/D	50 MG/KG/D	100 MG/KG/D	150 MG/KG/D
EXTERNAL					
Litters Evaluated	N	11	10	11	10
Fetuses Evaluated	N	152	148	156	123
Live	N	152	148	156	123
Dead	N	0	0	0	0
ABDOMEN, OMPHALOCELE					
Fetal Incidence	N	0	0	0	1
Litter Incidence	N	0	0	0	1
VESTIGIAL TAIL					
Fetal Incidence	N	0	0	0	1
Litter Incidence	N	0	0	0	1
ANAL ATRESIA					
Fetal Incidence	N	0	0	0	1
Litter Incidence	N	0	0	0	1
TOTAL FETAL EXTERNAL MALFORMATIONS					
Fetal Incidence	N	0	0	0	2
Litter Incidence	N	0	0	0	2

R. C. Keener/SMG 6-19-92

RH-7592: Oral (Gavage) Developmental
Toxicity Screen in Rats
Protocol No. 86P-485 Report No. 87R-014

BEST COPY AVAILABLE

Table 7: Fetal Malformations (Cont'd)

VISCERAL	DOSAGE	0 MG/KG/D	50 MG/KG/D	100 MG/KG/D	150 MG/KG/D
Litters Evaluated	N	11	0	0	10
Fetuses Evaluated	N	79	0	0	66
Live	N	79	0	0	66
Dead	N	0	0	0	0
HEART, VENTRICULAR SEPTAL DEFECT					
Fetal Incidence	N	0			1
Litter Incidence	N	0			1
INNOMINATE, NONE					
Fetal Incidence	N	0			1
Litter Incidence	N	0			1
TOTAL FETAL SOFT TISSUE MALFORMATIONS					
Fetal Incidence	N	0			2
Litter Incidence	N	0			2

COMPANY CONFIDENTIAL

R. L. Keener/Smb 6-19-92

RH-7592: Oral (Gavage Developmental
Toxicity Screen in Rats
Protocol No. 86P-485 Report No. 87R-014

BEST COPY AVAILABLE

Table 7: Fetal Malformations (Cont'd)

	DOSAGE	0 MG/KG/D	50 MG/KG/D	100 MG/KG/D	150 MG/KG/D
SKELETAL					
Litters Evaluated	N	11	0	0	10
Fetuses Evaluated	N	152	0	0	122
Live	N	152	0	0	122
Dead	N	0	0	0	0
RIB, 12TH, NONE					
Fetal Incidence	N	0			1
Litter Incidence	N	0			1
TOTAL FETAL SKELETAL	MALFORMATIONS				
Fetal Incidence	N	0			1
Litter Incidence	N	0			1

R. L. Keener/SMG 6-15-92

RH-7592: Oral (Gavage) Developmental
Toxicity Screen in Rats
Protocol No. 86P-485 Report No. 87R-014

BEST COPY AVAILABLE

Table 8: Fetal Developmental Variations

VISCERAL	DOSAGE	0 MG/KG/D	50 MG/KG/D	100 MG/KG/D	150 MG/KG/D
Litters Evaluated	N	11	10	11	10
Fetuses Evaluated	N	152	148	156	123
Live	N	152	148	156	123
Dead	N	0	0	0	0
HEMATOMA, HEAD, SIDE, RT					
Fetal Incidence	N	1	0	0	0
Litter Incidence	N	1	0	0	0
TOTAL FETAL EXTERNAL VARIATIONS					
Fetal Incidence	N	1	0	0	0
Litter Incidence	N	1	0	0	0

R. L. Keener/SKG 6-19-92

RH-7592: Oral (Gavage) Developmental
Toxicity Screen in Rats
Protocol No. 86P-485 Report No. 87R-014

BEST COPY AVAILABLE

Table 8: Fetal Developmental Variations (Cont'd)

SKELETAL	DOSAGE	0 MG/KG/D	50 MG/KG/D	100 MG/KG/D	150 MG/KG/D
Litters Evaluated	N	11	0	0	10
Fetuses Evaluated	N	152	0	0	122
Live	N	152	0	0	122
Dead	N	0	0	0	0
VERTEBRE, LUMBAR, 5 PRESENT					
Fetal Incidence	N	0			1
Litter Incidence	N	0			1
STERNEBRA, MISALINGED					
Fetal Incidence	N	2			3
Litter Incidence	N	2			1
RIB, RUDIMENTARY 14TH					
Fetal Incidence	N	2			6
Litter Incidence	N	2			2
TOTAL FETAL SKELETAL	VARIATIONS				
Fetal Incidence	N	4			10
Litter Incidence	N	4			3

COMPANY CONFIDENTIAL

R. L. Keener/SMG. 6-19-88

RH-7592: Oral (Gavage) Developmental Toxicity Screen in Rats

Protocol No. 86P-485 Report No. 87R-014

BEST COPY AVAILABLE

Table 9: Fetal Variations Due to Retarded Development

	DOSAGE	0 MG/KG/D	50 MG/KG/D	100 MG/KG/D	150 MG/KG/D
SKELETAL					
Litters Evaluated	N	11	0	0	10
Fetuses Evaluated	N	152	0	0	122
Live	N	152	0	0	122
Dead	N	0	0	0	0
HYOID, UNOSSIFIED					
Fetal Incidence	N	2			1
Litter Incidence	N	2			1
VERTEBRA, THORACIC, DUMBBELLED					
Fetal Incidence	N	3			4
Litter Incidence	N	2			3
VERTEBRA, THORACIC, UNOSSIFIED					
Fetal Incidence	N	1			1
Litter Incidence	N	1			1
VERTEBRA, THORACIC, BIPARTITE					
Fetal Incidence	N	1			4
Litter Incidence	N	1			2
VERTEBRA, LUMBAR, UNOSSIFIED					
Fetal Incidence	N	0			1
Litter Incidence	N	0			1
STERNEBRA, UNOSSIFIED					
Fetal Incidence	N	1			8
Litter Incidence	N	1			4
STERNEBRA, BIPARTITE					
Fetal Incidence	N	0			3
Litter Incidence	N	0			2
STERNEBRA, CARTILAGE NOT FUSED					
Fetal Incidence	N	0			1
Litter Incidence	N	0			1
STERNEBRA, PARTIALLY OSSIFIED					
Fetal Incidence	N	1			0
Litter Incidence	N	1			0

RH-7592: Oral (Gavage) Developmental
Toxicity Screen in Rats
Protocol No. 86P-485 Report No. 87R-014

BEST COPY AVAILABLE

Table 9: Fetal Variations Due to Retarded Development (Cont'd)

SKELETAL	DOSAGE	0 MG/KG/D	50 MG/KG/D	100 MG/KG/D	150 MG/KG/D
Litters Evaluated	N	11	0	0	10
Fetuses Evaluated	N	152	0	0	122
Live	N	152	0	0	122
Dead	N	0	0	0	0
RIB, PARTIALLY OSSIFIED					
Fetal Incidence	N	0			3
Litter Incidence	N	0			1
RIB, WAVY					
Fetal Incidence	N	1			0
Litter Incidence	N	1			0
PUBIS, PARTIALLY OSSIFIED					
Fetal Incidence	N	3			8
Litter Incidence	N	2			3
TOTAL FETAL SKELETAL RETARDATIONS					
Fetal Incidence	N	12			20
Litter Incidence	N	8			5

R.L. Keener/SMG 6-19-92

BEST COPY AVAILABLE

RH-7592: Oral (Gavage) Developmental Toxicity Screen in Rats

Protocol No. 86P-485 Report No. 87R-014

Table 10

Total Fetal Alterations

	Daily Dose (mg/kg) 0	50	100	150
Malformations				
Total No. Fetuses with Malformations(litters)	0(0)	a	a	6(6) 5(5)*
Mean % Affected Fetuses/Litter	0.0	a	a	4.0
(± SEM)	0.00	a	a	1.35
Variations				
Total No. Fetuses with Developmental Variations(litters)	5(4)	a	a	10(3)
Mean % Affected Fetuses/Litter	3.6	a	a	8.8
(± SEM)	1.61	a	a	5.15
Total No. Fetuses with Variations Due to Retarded Development(litters)	12(8)	a	a	20(5)
Mean % Affected Fetuses/Litter	7.6	a	a	13.97
(± SEM)	2.03	a	a	5.57
Total Variations				
Total No. Fetuses with Variations(litters)	17(9)	a	a	24(5)
Mean % Affected Fetuses/Litter	11.2	a	a	16.6
(± SEM)	3.22	a	a	6.48

a Fetuses were not examined for visceral or skeletal alterations.

* Significantly different from control value, $p \leq 0.05$.

UNITED STATES ENVIRONMENTAL PROTECTION AGENCY
WASHINGTON, D.C. 20460

Ronald L. Keener, Ph.D.
Regulatory Affairs Director, Product Integrity Department
Rohm and Haas Company
Independence Mall West
Philadelphia, Pennsylvania 19105

OFFICE OF
PREVENTION, PESTICIDES AND
TOXIC SUBSTANCES

APR 18 1995

EPA acknowledges the receipt of information submitted by your organization under Section 8(e) of the Toxic Substances Control Act (TSCA). For your reference, copies of the first page(s) of your submission(s) are enclosed and display the TSCA §8(e) Document Control Number (e.g., 8EHQ-00-0000) assigned by EPA to your submission(s). Please cite the assigned 8(e) number when submitting follow-up or supplemental information and refer to the reverse side of this page for "EPA Information Requests".

All TSCA 8(e) submissions are placed in the public files unless confidentiality is claimed according to the procedures outlined in Part X of EPA's TSCA §8(e) policy statement (43 FR 11110, March 16, 1978). Confidential submissions received pursuant to the TSCA §8(e) Compliance Audit Program (CAP) should already contain information supporting confidentiality claims. This information is required and should be submitted if not done so previously. To substantiate claims, submit responses to the questions in the enclosure "Support Information for Confidentiality Claims". This same enclosure is used to support confidentiality claims for non-CAP submissions.

Please address any further correspondence with the Agency related to this TSCA 8(e) submission to:

Document Processing Center (7407)
Attn: TSCA Section 8(e) Coordinator
Office of Pollution Prevention and Toxics
U.S. Environmental Protection Agency
Washington, D.C. 20460-0001

EPA looks forward to continued cooperation with your organization in its ongoing efforts to evaluate and manage potential risks posed by chemicals to health and the environment.

Sincerely,

Terry R. O'Bryan

Terry R. O'Bryan
Risk Analysis Branch

Enclosure 12246A

Recycled/Recyclable
Printed with Soy/Canola Ink on paper that contains at least 50% recycled fiber

Triage of 8(e) Submissions

Date sent to triage: APR 20 1995

NON-CAP (CAP)

Submission number: 12246A

TSCA Inventory: Y N (D)

Study type (circle appropriate):

Group 1 - Dick Clements (1 copy total)

ECO AQUATO

Group 2 - Ernie Falke (1 copy total)

ATOX SBTOX SEN w/NEUR

Group 3 - Elizabeth Margosches (1 copy each)

STOX CTOX EPI (RTOX) GTOX

STOX/ONCO CTOX/ONCO IMMUNO CYTO NEUR

Other (FATE, EXPO, MET, etc.):

Notes:

THIS IS THE ORIGINAL 8(e) SUBMISSION; PLEASE REFILE AFTER TRIAGE DATABASE ENTRY

For Contractor Use Only

entire document: (0) 1 2 **pages** 1 **pages** 1,2,3,4,5

Notes:

Contractor reviewer : PDK **Date:** 4/3/95

CECATS\TRIAGE TRACKING DBASE ENTRY FORM

CECATS DATA:
Submission # 8EHQ- 0992 -12246 SEQ. A

TYPE: INT. SUPP FLWP

SUBMITTER NAME: Rohm and Haas Company

INFORMATION REQUESTED: FLWP DATE:
0501 NO INFO REQUESTED
0502 INFO REQUESTED (TECH)
0503 INFO REQUESTED (VOL ACTIONS)
0504 INFO REQUESTED (REPORTING RATIONALE)

DISPOSITION:
0639 REFER TO CHEMICAL SCREENING
0678 CAP NOTICE

VOLUNTARY ACTIONS:
0401 NO ACTION REPORTED
0402 STUDIES PLANNED/UNDERWAY
0403 NOTIFICATION OF WORKERS/USERS
0404 LABEL/MSDS CHANGES
0405 PROCESS/HANDLING CHANGES
0406 APP/USE DISCONTINUED
0407 PRODUCTION DISCONTINUED
0408 CONFIDENTIAL

SUB. DATE: 08/26/92 OTS DATE: 09/08/92 CSRAD DATE: 02/27/95

BEST COPY AVAILABLE

CHEMICAL NAME: 1H-1,2,4-triazole-1-propanenitrile, alpha-[2-(4-chlorophenyl)-ethyl-alpha-phenyl-

CAS#: 114369-43-6

INFORMATION TYPE:		P F C	INFORMATION TYPE:		P F C	INFORMATION TYPE:		P F C
0201	ONCO (HUMAN)	01 02 04	0216	EPI/CLIN	01 02 04	0241	IMMUNO (ANIMAL)	01 02 04
0202	ONCO (ANIMAL)	01 02 04	0217	HUMAN EXPOS (PROD CONTAM)	01 02 04	0242	IMMUNO (HUMAN)	01 02 04
0203	CELL TRANS (IN VITRO)	01 02 04	0218	HUMAN EXPOS (ACCIDENTAL)	01 02 04	0243	CHEM/PHYS PROP	01 02 04
0204	MUTA (IN VITRO)	01 02 04	0219	HUMAN EXPOS (MONITORING)	01 02 04	0244	CLASTO (IN VITRO)	01 02 04
0205	MUTA (IN VIVO)	01 02 04	0220	ECO/AQUA TOX	01 02 04	0245	CLASTO (ANIMAL)	01 02 04
0206	REPRO/TERATO (HUMAN)	01 02 04	0221	ENV. OCCC/REL/FATE	01 02 04	0246	CLASTO (HUMAN)	01 02 04
0207	REPRO/TERATO (ANIMAL)	01 02 04	0222	EMER INCI OF ENV CONTAM	01 02 04	0247	DNA DAM/REPAIR	01 02 04
0208	NEURO (HUMAN)	01 02 04	0223	RESPONSE REQEST DELAY	01 02 04	0248	PROD/USE/PROC	01 02 04
0209	NEURO (ANIMAL)	01 02 04	0224	PROD/COMP/CHEM ID	01 02 04	0251	MSDS	01 02 04
0210	ACUTE TOX. (HUMAN)	01 02 04	0225	REPORTING RATIONALE	01 02 04	0299	OTHER	01 02 04
0211	CHR. TOX. (HUMAN)	01 02 04	0226	CONFIDENTIAL	01 02 04			
[illegible]	~~ACUTE TOX. (ANIMAL)~~	[illegible]	0227	ALLERG (HUMAN)	01 02 04			
0213	SUB ACUTE TOX (ANIMAL)	01 02 04	0228	ALLERG (ANIMAL)	01 02 04			
0214	SUB CHRONIC TOX (ANIMAL)	01 02 04	0239	METAB/PHARMACO (ANIMAL)	01 02 04			
0215	CHRONIC TOX (ANIMAL)	01 02 04	0240	METAB/PHARMACO (HUMAN)	01 02 04			

TRIAGE DATA:	NON-CBI INVENTORY	ONGOING REVIEW	SPECIES	TOXICOLOGICAL CONCERN:	USE:	PRODUCTION:
	YES	YES (DROP/REFER)	RAT	LOW		
CAS SR	NO	NO (CONTINUE)		MED		
	IN TERMINI	REFER		HIGH		

COMMENTS: garage, developmental

150 mg/Kg - dec BW gain, dec fetal wt, inc incidence of litters with malformed fetuses
100 mg/Kg - dec BW gain NOAEL for developmental tox.
50 mg/Kg - NOAEL for maternal toxicity